Replies to post #238868 on Innovation Pharmaceuticals Inc (IPIX)

[MXAMDUD]

2 are dead - K and P

[MinnieM]

Prurisol ph2b psoriasis trial results need to come out before you can count it's value in a buyout.

If good, having two drugs (Brilacidin and Prurisol) proven in completed ph 2's gives more value than just a single drug.

Kevetrin is a bit of a crap shoot as far as anyone paying a decent amount for it at this point in time. But, I haven't a clue as to whom Leo is talking to about it. Some entities will give it more potential value than others.

Bottom line, none of us know what to expect at this time in terms of dollars. I'm still holding since I believe there is a reasonable chance of Leo putting a deal together in the very near future. I just don't look for the high numbers that you expect. Hopefully, you are correct. ;)







In Reply to 'petemantx'
How many biotech companies have 3 drugs at the same time finished w/ Phase 2 trials?

Add in that all 3 appear safe beyond a doubt and address massive multiple markets?

If you don't think our drugs are disruptive your query is valid, if you think we have cutting edge science that will address lots of problems resulting in massive revenues, then your query is invalid.

I am on the side of disruptive.

[NanoEngineer]

I understand your point of view but the value of something is only represented by what the market is willing to pay for it. And for now, this value is quite low.

The current discrepancy between the potential value (*your value*) and the market value is exactly why I think a buyout is unlikely.
I you (and Leo) think for example that the IPIX pipeline is worth 10 billions (about $50 per share given about 200 millions shares fully diluted) this means that a BP would have to pay 100 times the current market cap to buy IPIX. I think it is extremely unlikely to occur.